Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.

Abstract

Background Inflammation of the arterial wall plays a central role in the pathogenesis of atherosclerosis. Among patients with rheumatic diseases, anti-rheumatic medication reduces the incidence of cardiovascular (CV) diseases, but only few studies have addressed their cardioprotective effects on patients with no rheumatic diseases. Hydroxychloroquine (HCQ… (More)
DOI: 10.1093/ehjcvp/pvw035

Topics

3 Figures and Tables

Cite this paper

@article{Hartman2017HydroxychloroquineFT, title={Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.}, author={Otto Hartman and Petri T. Kovanen and Jukka Y. A. Lehtonen and Kari K Eklund and Juha Sinisalo}, journal={European heart journal. Cardiovascular pharmacotherapy}, year={2017}, volume={3 2}, pages={92-97} }